US 11878961
Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer
granted A61KA61K31/4196A61K31/502
Quick answer
US patent 11878961 (Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer) held by The Board of Regents of the University of Texas System expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K31/4196, A61K31/502, A61K45/06